Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Neurology Drugs in Phase I Clinical Development in SWEDEN

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              AlzeCure Pharma AB

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              AlzeCure Announces Positive Data From Clinical Study with ACD856

              Contact the Supplier

              Lead Product(s): ACD856

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 04, 2020

              Details:

              Data show that ACD856, has a good pharmacokinetic profile with a significantly shorter human half-life than its predecessor ACD855 and that the candidate is suitable for further clinical development such as oral treatment of Alzheimer's disease, among others.

              Orexo

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain

              Contact the Supplier

              Lead Product(s): Ketorolac

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 29, 2020

              Details:

              OX338 demonstrated improved bioavailability and tolerability compared to commercially available reference product.

              PharmaCompass__DigitalAd